A semisynthetic taxane
Related Products
Labeled Version(s)
28488Cabazitaxel-d9
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cabazitaxel

Item No. 22262

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-benzenepropanoic acid, (αR,βS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester
CAS Number
183133-96-2
Synonyms
  • TXD 258
  • XRP 6258
Molecular Formula
C45H57NO14
Formula Weight
835.9
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlDMSO:PBS (pH 7.2) (1:10): 0.1 mg/mlEthanol: 1.5 mg/ml
λmax
229 nm
SMILES
CC(C1=C(C)[C@@H](OC([C@H](O)[C@@H](NC(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C3)(C)[C@]3(O)[C@@H](OC(C4=CC=CC=C4)=O)[C@@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]6OC)([H])[C@]6(C)C([C@@H]1OC)=O
InChi Code
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
InChi Key
BMQGVNUXMIRLCK-OAGWZNDDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $49

    Add

    10 mg

    $73

    Add

    25 mg

    $154

    Add

    50 mg

    $283

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Cabazitaxel is a second generation semisynthetic taxane derived from 10-deacetylbaccatin III (Item No. 22261).1 It stabilizes microtubule assembly by reducing lag time for tubulin assembly (LT50 = 100 nM) and the rate of cold-induced microtubule depolymerization (IC50s = 100-250 nM) in vitro. Cabazitaxel inhibits proliferation of P388, HL-60, Calc18, and KB cells (IC50s = 4-41 nM), as well as P-glycoprotein-expressing, drug-resistant versions of these cell lines (IC50s = 16-414 nM). In vivo, cabazitaxel dose-dependently reduces tumor growth in docetaxel-susceptible N87 human gastric carcinoma and docetaxel-resistant UISO BCA-1 breast cancer mouse xenograft models. Formulations containing cabazitaxel have been used in combination with prednisone in the treatment of hormone-refractory metastatic prostate cancer.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Vrignaud, P., Sémiond, D., Lejeune, P., et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 19(11), 2973-2983 (2013).